Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1

Detalles Bibliográficos
Autores principales: Cantrell, W., Lee, P., Mendelsohn, A.M., Rozzo, S.J., Liao, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359438/
https://www.ncbi.nlm.nih.gov/pubmed/33460505
http://dx.doi.org/10.1111/jdv.17124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359438/
https://www.ncbi.nlm.nih.gov/pubmed/33460505
http://dx.doi.org/10.1111/jdv.17124

Ejemplares similares